Repligen Corp RGEN
๐ Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1986-04-29 |
| Shares Out. | 56,440,000 |
| Website | repligen.com/ โ |
| Phone | 13026587581 |
| Employees | 2,000 |
| Revenue | $204.1M |
| Gross Profit | $110.0M |
| Net Income | $5.0M |
| Free Cash Flow | $112.0M |
| Total Assets | $2.95B |
| Total Liabilities | $838.1M |
| Equity | $2.11B |
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Repligen Corp is a publicly traded company under the ticker symbol RGEN on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
28 analysts (2026-09-01)

